TEDCO backs KRAS cancer startup Sirius with $25K concept investment
What's the deal? TEDCODealroom has a profile for this one. Try Dealroom →, the Maryland Technology Development Corporation, has invested $25,000 in SiriusDealroom has a profile for this one. Try Dealroom → Biotech Ventures through its Concept Capital program. The Frederick, Maryland-based startup is a discovery-stage oncology company working to overcome resistance to KRAS-targeted cancer therapies.
What's the endgame? Sirius is building a platform that pairs high-content phenotypic and functional profiling with mass spectrometry to speed up drug discovery. It is developing small-molecule candidates designed to extend how long patients respond to KRAS inhibitors.
Why now? The company aims to identify validated KRAS combination assets suitable for licensing within 18 to 24 months. "With this funding, we can accelerate our discovery program and identify promising combination therapies," said chief executive officer Frantz Jean-François.
What's the money for? TEDCO's Concept Capital program provides early-stage funding to help tech companies launch and grow. "Supporting innovations like this is central to TEDCO's mission of strengthening Maryland's life sciences ecosystem," said Justin Ferguson, innovation manager for venture development at TEDCO.
The signal: The investment reflects Maryland's push to anchor life sciences startups around federal institutions such as the National Institutes of HealthDealroom has a profile for this one. Try Dealroom → and the Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom →. TEDCO chief executive officer Troy LeMaile-Stovall framed Sirius as an example of "world-class scientific talent tackling some of the toughest challenges in medicine."
Read more: citybiz.co
Image credit: Generated with Gemini
